Stock DBI DEUTSCHE BIOTECH INNOVATIV AG
Add to a list
To use this feature you must be a member
Log inSign up

Company Deutsche Biotech Innovativ AG

Equities

DBI

DE000A0Z25L1

Biotechnology & Medical Research

End-of-day quote BOERSE DUESSELDORF
Other stock markets
 23:00:00 02/05/2024 BST 		5-day change 1st Jan Change
1.35 EUR 0.00% Intraday chart for Deutsche Biotech Innovativ AG 0.00% -82.80%
2023 Deutsche Biotech Innovativ AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2018 Adrenomed AG announced that it has received €24.2 million in funding from Deutsche Biotech Innovativ AG, Wellington Ventures, HBM Healthcare Investments Ltd., and other investors CI

Business Summary

Deutsche Biotech Innovativ AG, formerly, Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients and develops targeted therapies to prevent septic shock and inhibit tumour growth, as well as a small molecule drug for breast cancer prevention, Procizumab, focus on antibody-based therapy for the treatment of organ failure in patients with cardiogenic shock. Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest.

Number of employees: 1

Sales per Business

EUR in Million2018Weight2019Weight Delta
Investment and Related Activities
100.0 %
0 100.0 % 0 100.0 % -91.66%

Sales per region

EUR in Million2018Weight2019Weight Delta
Germany
100.0 %
0 100.0 % 0 100.0 % -91.66%

Managers

Managers TitleAgeSince
Bernd Wegener CEO
 Chief Executive Officer 76 31/12/08
Metod Miklus COO
 Chief Operating Officer 65 06/10/19

Members of the board

Members of the board TitleAgeSince
Bernd Wegener CEO
 Chief Executive Officer 76 31/12/08
Metod Miklus COO
 Chief Operating Officer 65 06/10/19
Renke Lührs CHM
 Chairman 64 14/02/11
Eva Gardyan-Eisenlohr BRD
 Director/Board Member - -
Siegmund Karasch BRD
 Director/Board Member 59 04/07/18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 947,296 937,823 ( 99.00 %) 0 99.00 %

Shareholders

NameEquities%Valuation
HINKEL & Cie. Vermögensverwaltung AG
0.8182 %
7,751 0.8182 % 39 781 €

Company contact information

Deutsche Biotech Innovativ AG

Neuendorfstrasse 15a

16761, Hennigsdorf

+49 3302 20 77 824

http://www.dbi-ag.de
address Deutsche Biotech Innovativ AG(DBI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DEUTSCHE BIOTECH INNOVATIV AG Stock Deutsche Biotech Innovativ AG
-82.80% 1.38M
MODERNA, INC. Stock Moderna, Inc.
+29.03% 48.16B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.10% 41.73B
LONZA GROUP AG Stock Lonza Group AG
+43.45% 41.03B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.48% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.74% 18.96B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+9.06% 12.92B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.01% 12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.51% 11.77B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DBI Stock
  4. Company Deutsche Biotech Innovativ AG